Wall Street Wants the Best Patents, Not the Best Drugs
A Chinese twist in the tale involving Hepatitis C drug Sofosbuvir
Gilead loses key patent claims for Sovaldi in China, opening door to earlier generic entry
AbbVie faces hepatitis C patent challenge in India
Brief: AbbVie Hepatitis C Treatment Patents Challenged In India For Evergreening
I-MAK & Delhi Network of Positive People File Opposition to Prevent AbbVie Patent Grant on Hepatitis C Treatment
With Only 15% of Diagnosed HCV Patients Receiving Treatment, the Non-Profit I-MAK Hopes to Shift the National Conversation on Drug Pricing
Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents
Major Win for Patients as Brazil Rejects a Key Patent on Gilead Hepatitis C Drug and European Court of Justice Opinion Denies Patent Extension to Gilead’s HIV Drug
Tahir Amin: Increasing Access to Affordable HIV Drugs Through Patent Opposition